Molecular Neurodegeneration

(The TQCC of Molecular Neurodegeneration is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-01-01 to 2024-01-01.)
Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances498
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease375
PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson’s disease237
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease178
The role of TDP-43 mislocalization in amyotrophic lateral sclerosis161
Initiation and propagation of α-synuclein aggregation in the nervous system142
Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway105
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease96
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration94
APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease94
Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease91
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics91
Neuropathology and molecular diagnosis of Synucleinopathies85
Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease85
Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model84
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis81
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery81
New approaches to symptomatic treatments for Alzheimer’s disease81
Cellular and pathological heterogeneity of primary tauopathies78
“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies77
METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer’s disease through aberrant cell cycle events76
Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer’s disease74
TDP-43 Pathology in Alzheimer’s Disease74
Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry72
Tauopathies: new perspectives and challenges70
Glycosphingolipids and neuroinflammation in Parkinson’s disease70
Post-infection cognitive impairments in a cohort of elderly patients with COVID-1970
Solving neurodegeneration: common mechanisms and strategies for new treatments70
NLRP12 collaborates with NLRP3 and NLRC4 to promote pyroptosis inducing ganglion cell death of acute glaucoma70
Promoting tau secretion and propagation by hyperactive p300/CBP via autophagy-lysosomal pathway in tauopathy68
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies67
Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers64
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns63
P2RX7 inhibitor suppresses exosome secretion and disease phenotype in P301S tau transgenic mice59
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology58
Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination57
Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer’s disease56
Microbial involvement in Alzheimer disease development and progression55
PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency54
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions53
Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders53
Circulating cell-free mitochondrial DNA levels in Parkinson’s disease are influenced by treatment51
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases50
Constitutively active SARM1 variants that induce neuropathy are enriched in ALS patients49
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives48
Dipeptide repeat proteins inhibit homology-directed DNA double strand break repair in C9ORF72 ALS/FTD48
A pharmacological chaperone improves memory by reducing Aβ and tau neuropathology in a mouse model with plaques and tangles48
Adult-onset CNS myelin sulfatide deficiency is sufficient to cause Alzheimer’s disease-like neuroinflammation and cognitive impairment47
Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia47
Impaired NHEJ repair in amyotrophic lateral sclerosis is associated with TDP-43 mutations46
The Alzheimer’s disease-associated protective Plcγ2-P522R variant promotes immune functions46
VGF-derived peptide TLQP-21 modulates microglial function through C3aR1 signaling pathways and reduces neuropathology in 5xFAD mice46
Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study46
CNS axonal degeneration and transport deficits at the optic nerve head precede structural and functional loss of retinal ganglion cells in a mouse model of glaucoma44
The CD33 short isoform is a gain-of-function variant that enhances Aβ1–42 phagocytosis in microglia44
Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain44
Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach43
Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson’s disease40
Trem2 deficiency differentially affects phenotype and transcriptome of human APOE3 and APOE4 mice39
Clusterin secreted from astrocyte promotes excitatory synaptic transmission and ameliorates Alzheimer’s disease neuropathology39
Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer’s disease brain39
FRET-based Tau seeding assay does not represent prion-like templated assembly of Tau filaments38
A novel systems biology approach to evaluate mouse models of late-onset Alzheimer’s disease38
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis37
Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer’s disease mutations but not by inhibition of BACE137
Alzheimer’s disease – the journey of a healthy brain into organ failure36
Identification of sixteen novel candidate genes for late onset Parkinson’s disease34
Cholesterol alters mitophagy by impairing optineurin recruitment and lysosomal clearance in Alzheimer’s disease34
Flow-cytometric microglial sorting coupled with quantitative proteomics identifies moesin as a highly-abundant microglial protein with relevance to Alzheimer’s disease34
Deciphering cellular transcriptional alterations in Alzheimer’s disease brains33
The role of inflammasomes in vascular cognitive impairment33
Elevated methylation levels, reduced expression levels, and frequent contractions in a clinical cohort of C9orf72 expansion carriers32
The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored32
The informed road map to prevention of Alzheimer Disease: A call to arms32
CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer’s disease32
α-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment31
Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration31
Enhancing GABAergic signaling ameliorates aberrant gamma oscillations of olfactory bulb in AD mouse models31
TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target30
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application30
Sex-dependent calcium hyperactivity due to lysosomal-related dysfunction in astrocytes from APOE4 versus APOE3 gene targeted replacement mice30
From basic research to the clinic: innovative therapies for ALS and FTD in the pipeline30
The landscape of human tissue and cell type specific expression and co-regulation of senescence genes29
Altered network properties in C9ORF72 repeat expansion cortical neurons are due to synaptic dysfunction29
Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer’s disease29
Tauopathy-associated tau modifications selectively impact neurodegeneration and mitophagy in a novel C. elegans single-copy transgenic model29
Modeling the β-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimer’s disease29
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM229
Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain29